BRIGHT MINDS BIOSCIENCES INC. overview

Toronto, Ontario--(Newsfile Corp. - Le 12 juillet/July 2023) - Bright Minds Biosciences Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every five (5) pre-consolidated common shares. As a result, the outstanding shares of the company will be reduced to approximately 3,772,071 common shares. The name and symbol will not change. Please note that all open orders will be canceled at the close of business on...

VANCOUVER, British Columbia, July 11, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“ Bright Minds ” or the “ Company ”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, announces that, further to its news release on June 22, 2023, the Company will consolidate its common shares (the “ Common Shares ”) on a five (5) to one (1) basis (the “ Consolidation ”)....

VANCOUVER, British Columbia, June 22, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“ Bright Minds ” or the “ Company ”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, announces that it intends to consolidate its common shares (the “ Common Shares ”) on a five (5) to one (1) basis (the “ Consolidation ”). The Consolidation has been approved by the...

-- BMB-202 is a highly selective 5-HT 2A agonist that exhibits a more than 30-fold selectivity over 5-HT 2C and more than 500-fold selectivity over 5-HT 2B -- -- BMB-202 is the first clinical candidate from an extensive portfolio of selective 5-HT 2A and 5-HT 2A/2C agonists inspired from natural compound scaffolds -- VANCOUVER, British Columbia, April 19, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“ Bright Minds ” or the “ Company ”), a biotechnology...

— Presentation entitled "BMB-101: A selective 5-HT 2C agonist in clinical trials with therapeutic utility" — — First-in-human Phase 1 trial for lead program, BMB-101, is underway in Australia — VANCOUVER, British Columbia, April 10, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“ Bright Minds ” or the “ Company ”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and...

-- First-in-human Phase 1 trial for lead program, BMB-101, a highly selective 5-HT 2C agonist, is underway in Australia -- -- Company has transitioned from a discovery to a development organization – -- Company to attend BIO-Europe Spring Conference in Basel, Switzerland, March 20-22, 2023 -- VANCOUVER, British Columbia, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“ Bright Minds ” or the “ Company ”), a biotechnology company focused on...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES VANCOUVER, British Columbia, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“ Bright Minds ” or the “ Company ”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced the...

VANCOUVER, British Columbia, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“ Bright Minds ” or the “ Company ”) announces that it has received a letter (the “ Deficiency Letter ”) from the Nasdaq Stock Market LLC (“ NASDAQ ”) dated February 2, 2023, stating that following the resignation of Dr. Williamson from the Company’s board of directors and audit committee, the Company no longer complies with NASDAQ’s independent director and...